Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Bradley Foster & Sargent Inc. CT

Bradley Foster & Sargent Inc. CT boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 4.6% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 67,244 shares of the company’s stock after acquiring an additional 2,977 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Novo Nordisk A/S were worth $9,598,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in NVO. First PREMIER Bank acquired a new stake in Novo Nordisk A/S during the 1st quarter worth $25,000. 1620 Investment Advisors Inc. acquired a new stake in Novo Nordisk A/S during the 2nd quarter worth $25,000. Dixon Mitchell Investment Counsel Inc. acquired a new stake in Novo Nordisk A/S during the 1st quarter worth $26,000. Orion Capital Management LLC acquired a new stake in Novo Nordisk A/S during the 1st quarter worth $26,000. Finally, Gilliland Jeter Wealth Management LLC boosted its stake in Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after purchasing an additional 120 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 3.6 %

Novo Nordisk A/S stock opened at $132.00 on Wednesday. Novo Nordisk A/S has a twelve month low of $86.96 and a twelve month high of $148.15. The stock’s fifty day simple moving average is $133.74 and its 200-day simple moving average is $133.20. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $592.35 billion, a P/E ratio of 45.52, a P/E/G ratio of 1.48 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The company had revenue of $9.82 billion for the quarter, compared to analysts’ expectations of $9.91 billion. As a group, equities analysts expect that Novo Nordisk A/S will post 3.11 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were given a dividend of $0.5126 per share. This represents a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio is currently 24.83%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Monday, August 19th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Monday. BMO Capital Markets cut their target price on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a research report on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price on the stock. Finally, Argus boosted their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $145.17.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.